|
1
|
Fidler IJ: The pathogenesis of cancer
metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Joukov V, Pajusola K, Kaipainen A, Chilov
D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N and Alitalo K: A
novel vascular endothelial growth factor, VEGF-C, is a ligand for
the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
EMBO J. 15:290–298. 1996.PubMed/NCBI
|
|
3
|
Jeltsch M, Kaipainen A, Joukov V, Meng X,
Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK and Alitalo K:
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
Science. 276:1423–1425. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amioka T, Kitadai Y, Tanaka S, Haruma K,
Yoshihara M, Yasui W and Chayama K: Vascular endothelial growth
factor-C expression predicts lymph node metastasis of human gastric
carcinomas invading the submucosa. Eur J Cancer. 38:1413–1419.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
George ML, Tutton MG, Janssen F, Arnaout
A, Abulafi AM, Eccles SA and Swift RI: VEGF-A, VEGF-C, and VEGF-D
in colorectal cancer progression. Neoplasia. 3:420–427. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Niki T, Iba S, Tokunou M, Yamada T,
Matsuno Y and Hirohashi S: Expression of vascular endothelial
growth factors A, B, C, and D and their relationships to lymph node
status in lung adenocarcinoma. Clin Cancer Res. 6:2431–2439.
2000.PubMed/NCBI
|
|
7
|
Gunningham SP, Currie MJ, Han C, Robinson
BA, Scott PA, Harris AL and Fox SB: The short form of the
alternatively spliced flt-4 but not its ligand vascular endothelial
growth factor C is related to lymph node metastasis in human breast
cancers. Clin Cancer Res. 6:4278–4286. 2000.PubMed/NCBI
|
|
8
|
Favier B, Alam A, Barron P, Bonnin J,
Laboudie P, Fons P, Mandron M, Herault JP, Neufeld G, Savi P, et
al: Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes
human endothelial cell survival and migration. Blood.
108:1243–1250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Giger RJ, Cloutier JF, Sahay A, Prinjha
RK, Levengood DV, Moore SE, Pickering S, Simmons D, Rastan S, Walsh
FS, et al: Neuropilin-2 is required in vivo for selective axon
guidance responses to secreted semaphorins. Neuron. 25:29–41. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan L, Moyon D, Pardanaud L, Bréant C,
Karkkainen MJ, Alitalo K and Eichmann A: Abnormal lymphatic vessel
development in neuropilin 2 mutant mice. Development.
129:4797–4806. 2002.PubMed/NCBI
|
|
11
|
Pellet-Many C, Frankel P, Jia H and
Zachary I: Neuropilins: Structure, function and role in disease.
Biochem J. 411:211–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yasuoka H, Kodama R, Tsujimoto M,
Yoshidome K, Akamatsu H, Nakahara M, Inagaki M, Sanke T and
Nakamura Y: Neuropilin-2 expression in breast cancer: Correlation
with lymph node metastasis, poor prognosis, and regulation of CXCR4
expression. BMC Cancer. 9:2202009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cohen T, Herzog Y, Brodzky A, Greenson JK,
Eldar S, Gluzman-Poltorak Z, Neufeld G and Resnick MB: Neuropilin-2
is a novel marker expressed in pancreatic islet cells and endocrine
pancreatic tumours. J Pathol. 198:77–82. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lantuéjoul S, Constantin B, Drabkin H,
Brambilla C, Roche J and Brambilla E: Expression of VEGF,
semaphorin SEMA3F, and their common receptors neuropilins NP1 and
NP2 in preinvasive bronchial lesions, lung tumours, and cell lines.
J Pathol. 200:336–347. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawakami T, Tokunaga T, Hatanaka H, Kijima
H, Yamazaki H, Abe Y, Osamura Y, Inoue H, Ueyama Y and Nakamura M:
Neuropilin 1 and neuropilin 2 co-expression is significantly
correlated with increased vascularity and poor prognosis in
nonsmall cell lung carcinoma. Cancer. 95:2196–2201. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lang BH, Lo CY, Chan WF, Lam KY and Wan
KY: Prognostic factors in papillary and follicular thyroid
carcinoma: Their implications for cancer staging. Ann Surg Oncol.
14:730–738. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Salajegheh A, Pakneshan S, Rahman A,
Dolan-Evans E, Zhang S, Kwong E, Gopalan V, Lo CY, Smith RA and Lam
AK: Co-regulatory potential of vascular endothelial growth factor-A
and vascular endothelial growth factor-C in thyroid carcinoma. Hum
Pathol. 44:2204–2212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu XM, Lo CY, Lam AK, Lang BH, Leung P and
Luk JM: The potential clinical relevance of serum vascular
endothelial growth factor (VEGF) and VEGF-C in recurrent papillary
thyroid carcinoma. Surgery. 144:934–940; discussion 940–941. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yasuoka H, Kodama R, Hirokawa M, Takamura
Y, Miyauchi A, Inagaki M, Sanke T and Nakamura Y: Neuropilin-2
expression in papillary thyroid carcinoma: Correlation with VEGF-D
expression, lymph node metastasis, and VEGF-D-induced aggressive
cancer cell phenotype. J Clin Endocrinol Metab. 96:E1857–E1861.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Romitti M, Ceolin L, Siqueira DR, Ferreira
CV, Wajner SM and Maia AL: Signaling pathways in follicular
cell-derived thyroid carcinomas (review). Int J Oncol. 42:19–28.
2013.PubMed/NCBI
|
|
22
|
Goel HL, Bae D, Pursell B, Gouvin LM, Lu S
and Mercurio AM: Neuropilin-2 promotes branching morphogenesis in
the mouse mammary gland. Development. 138:2969–2976. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tai CK, Wang W, Lai YH, Logg CR, Parker
WB, Li YF, Hong JS, Sorscher EJ, Chen TC and Kasahara N: Enhanced
efficiency of prodrug activation therapy by tumor-selective
replicating retrovirus vectors armed with the Escherichia coli
purine nucleoside phosphorylase gene. Cancer Gene Ther. 17:614–623.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Su JL, Yang PC, Shih JY, Yang CY, Wei LH,
Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, et al: The
VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells.
Cancer Cell. 9:209–223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Issbrücker K, Marti HH, Hippenstiel S,
Springmann G, Voswinckel R, Gaumann A, Breier G, Drexler HC,
Suttorp N and Clauss M: p38 map kinase - a molecular switch between
VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J.
17:262–264. 2003.PubMed/NCBI
|
|
27
|
Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang
S, Wang W, Zhang J and Zhang Y: RNAi-mediated silencing of VEGF-C
inhibits non-small cell lung cancer progression by simultaneously
down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent
axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer.
47:2353–2363. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Affolter A, Fruth K, Brochhausen C,
Schmidtmann I, Mann WJ and Brieger J: Activation of
mitogen-activated protein kinase extracellular signal-related
kinase in head and neck squamous cell carcinomas after irradiation
as part of a rescue mechanism. Head Neck. 33:1448–1457. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hoshida T, Isaka N, Hagendoorn J, di
Tomaso E, Chen YL, Pytowski B, Fukumura D, Padera TP and Jain RK:
Imaging steps of lymphatic metastasis reveals that vascular
endothelial growth factor-C increases metastasis by increasing
delivery of cancer cells to lymph nodes: Therapeutic implications.
Cancer Res. 66:8065–8075. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goel HL, Pursell B, Chang C, Shaw LM, Mao
J, Simin K, Kumar P, Kooi CW Vander, Shultz LD, Greiner DL, et al:
GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine
pathway that contributes to breast cancer initiation. EMBO Mol Med.
5:488–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kurio N, Shimo T, Fukazawa T, Takaoka M,
Okui T, Hassan NM, Honami T, Hatakeyama S, Ikeda M, Naomoto Y and
Sasaki A: Anti-tumor effect in human breast cancer by TAE226, a
dual inhibitor for FAK and IGF-IR in vitro and in vivo. Exp Cell
Res. 317:1134–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu J and Brown RE: Morphoproteomic
confirmation of an activated nuclear factor-кBp65 pathway in
follicular thyroid carcinoma. Int J Clin Exp Pathol. 5:216–223.
2012.PubMed/NCBI
|
|
33
|
Liu W, Parikh AA, Stoeltzing O, Fan F,
McCarty MF, Wey J, Hicklin DJ and Ellis LM: Upregulation of
neuropilin-1 by basic fibroblast growth factor enhances vascular
smooth muscle cell migration in response to VEGF. Cytokine.
32:206–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Castresana MR and Newman WH:
Reactive oxygen and NF-kappaB in VEGF-induced migration of human
vascular smooth muscle cells. Biochem Biophys Res Commun.
285:669–674. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hall-Jackson CA, Goedert M, Hedge P and
Cohen P: Effect of SB 203580 on the activity of c-Raf in vitro and
in vivo. Oncogene. 18:2047–2054. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu P, Liu W, Wang L, Yang M and Du J: High
circulating VEGF level predicts poor overall survival in lung
cancer. J Cancer Res Clin Oncol. 139:1157–1167. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Y, Meng X, Zeng H, Guan Y, Zhang Q,
Guo S, Liu X and Guo Q: Serum vascular endothelial growth factor-C
levels: A possible diagnostic marker for lymph node metastasis in
patients with primary non-small cell lung cancer. Oncol Lett.
6:545–549. 2013.PubMed/NCBI
|
